Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):850–858. doi: 10.1054/bjoc.2001.2016

Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer

D Steinmann 1,2,1, M Bremer 1, D Rades 1, B Skawran 2, C Siebrands 2, J H Karstens 1, T Dörk 2,3
PMCID: PMC2375067  PMID: 11556836

Abstract

Mutations of the BRCA1 or BRCA2 genes have been shown to strongly predispose towards the development of contralateral breast cancer in patients from large multi-case families. In order to test the hypothesis that BRCA1 and BRCA2 mutations are more frequent in patients with bilateral breast cancer, we have investigated a hospital-based series of 75 consecutive patients with bilateral breast cancer and a comparison group of 75 patients with unilateral breast cancer, pairwise matched by age and family history, for mutations in the BRCA1 and BRCA2 genes. Five frameshift deletions (517delGT in BRCA1; 4772delA, 5946delCT, 6174delT and 8138del5 in BRCA2) were identified in patients with bilateral disease. No further mutations, apart from polymorphisms and 3 rare unclassified variants, were found after scanning the whole BRCA1 and BRCA2 coding sequence. Three pathogenic BRCA1 mutations (Cys61Gly, 3814del5, 5382insC) were identified in the group of patients with unilateral breast cancer. The frequencies of common BRCA1 and BRCA2 missense variants were not different between the 2 groups. In summary, we did not find a significantly increased prevalence of BRCA1 and BRCA2 mutations in a hospital-based cohort of German patients with bilateral breast cancer. We conclude that bilaterality of breast cancer on its own is not strongly associated with BRCA1 and BRCA2 mutations when adjusted for age and family history. The high frequency of bilateral disease in multi-case breast cancer families may be due to a familial aggregation of additional susceptibility factors modifying the penetrance of BRCA1 and BRCA2 mutations. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: contralateral breast cancer, BRCA1, BRCA2

Full Text

The Full Text of this article is available as a PDF (101.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Bergström R., Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer. 1985 Feb 1;55(3):643–647. doi: 10.1002/1097-0142(19850201)55:3<643::aid-cncr2820550328>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  2. Anderson D. E. Some characteristics of familial breast cancer. Cancer. 1971 Dec;28(6):1500–1504. doi: 10.1002/1097-0142(197112)28:6<1500::aid-cncr2820280623>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  3. Barker D. F., Almeida E. R., Casey G., Fain P. R., Liao S. Y., Masunaka I., Noble B., Kurosaki T., Anton-Culver H. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet Epidemiol. 1996;13(6):595–604. doi: 10.1002/(SICI)1098-2272(1996)13:6<595::AID-GEPI5>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  4. Bernstein J. L., Thompson W. D., Risch N., Holford T. R. The genetic epidemiology of second primary breast cancer. Am J Epidemiol. 1992 Oct 15;136(8):937–948. doi: 10.1093/oxfordjournals.aje.a116566. [DOI] [PubMed] [Google Scholar]
  5. Broeks A., Urbanus J. H., Floore A. N., Dahler E. C., Klijn J. G., Rutgers E. J., Devilee P., Russell N. S., van Leeuwen F. E., van 't Veer L. J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000 Feb;66(2):494–500. doi: 10.1086/302746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dunning A. M., Chiano M., Smith N. R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997 Feb;6(2):285–289. doi: 10.1093/hmg/6.2.285. [DOI] [PubMed] [Google Scholar]
  7. Durocher F., Shattuck-Eidens D., McClure M., Labrie F., Skolnick M. H., Goldgar D. E., Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 1996 Jun;5(6):835–842. doi: 10.1093/hmg/5.6.835. [DOI] [PubMed] [Google Scholar]
  8. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  9. Eccles D. M., Englefield P., Soulby M. A., Campbell I. G. BRCA1 mutations in southern England. Br J Cancer. 1998 Jun;77(12):2199–2203. doi: 10.1038/bjc.1998.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  11. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gershoni-Baruch R., Dagan E., Fried G., Kepten I., Robinson E. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet. 1999 Oct-Nov;7(7):833–836. doi: 10.1038/sj.ejhg.5200371. [DOI] [PubMed] [Google Scholar]
  13. Goss P. E., Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol. 1998 Jan;16(1):338–347. doi: 10.1200/JCO.1998.16.1.338. [DOI] [PubMed] [Google Scholar]
  14. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23;343(21):1566–1568. doi: 10.1056/NEJM200011233432111. [DOI] [PubMed] [Google Scholar]
  15. Healey C. S., Dunning A. M., Teare M. D., Chase D., Parker L., Burn J., Chang-Claude J., Mannermaa A., Kataja V., Huntsman D. G. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000 Nov;26(3):362–364. doi: 10.1038/81691. [DOI] [PubMed] [Google Scholar]
  16. Healey E. A., Cook E. F., Orav E. J., Schnitt S. J., Connolly J. L., Harris J. R. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993 Aug;11(8):1545–1552. doi: 10.1200/JCO.1993.11.8.1545. [DOI] [PubMed] [Google Scholar]
  17. Hislop T. G., Elwood J. M., Coldman A. J., Spinelli J. J., Worth A. J., Ellison L. G. Second primary cancers of the breast: incidence and risk factors. Br J Cancer. 1984 Jan;49(1):79–85. doi: 10.1038/bjc.1984.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Knudson A. G., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–823. doi: 10.1073/pnas.68.4.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kote-Jarai Z., Eeles R. A. BRCA1, BRCA2 and their possible function in DNA damage response. Br J Cancer. 1999 Dec;81(7):1099–1102. doi: 10.1038/sj.bjc.6690814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lamlum H., Al Tassan N., Jaeger E., Frayling I., Sieber O., Reza F. B., Eckert M., Rowan A., Barclay E., Atkin W. Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet. 2000 Sep 22;9(15):2215–2221. doi: 10.1093/oxfordjournals.hmg.a018912. [DOI] [PubMed] [Google Scholar]
  21. Larson G. P., Zhang G., Ding S., Foldenauer K., Udar N., Gatti R. A., Neuberg D., Lunetta K. L., Ruckdeschel J. C., Longmate J. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet Test. 1997;1(3):165–170. doi: 10.1089/gte.1997.1.165. [DOI] [PubMed] [Google Scholar]
  22. Martin A. M., Weber B. L. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000 Jul 19;92(14):1126–1135. doi: 10.1093/jnci/92.14.1126. [DOI] [PubMed] [Google Scholar]
  23. Mose S., Adamietz I. A., Thilmann C., Saran F., Pahnke R., Böttcher H. D. Die Prognose des bilateralen Mammakarzinoms im Vergleich zum unilateralen Mammatumor. Follow-up nach fünf und zehn Jahren. Strahlenther Onkol. 1995 Apr;171(4):207–213. [PubMed] [Google Scholar]
  24. Olsen J. H., Seersholm N., Boice J. D., Jr, Krüger Kjaer S., Fraumeni J. F., Jr Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study. Br J Cancer. 1999 Feb;79(3-4):673–679. doi: 10.1038/sj.bjc.6690106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Otterson G. A., Modi S., Nguyen K., Coxon A. B., Kaye F. J. Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. Am J Hum Genet. 1999 Oct;65(4):1040–1046. doi: 10.1086/302581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Peto J., Mack T. M. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000 Dec;26(4):411–414. doi: 10.1038/82533. [DOI] [PubMed] [Google Scholar]
  27. Phelan C. M., Rebbeck T. R., Weber B. L., Devilee P., Ruttledge M. H., Lynch H. T., Lenoir G. M., Stratton M. R., Easton D. F., Ponder B. A. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996 Mar;12(3):309–311. doi: 10.1038/ng0396-309. [DOI] [PubMed] [Google Scholar]
  28. Phillips K. A., Glendon G., Knight J. A. Putting the risk of breast cancer in perspective. N Engl J Med. 1999 Jan 14;340(2):141–144. doi: 10.1056/NEJM199901143400211. [DOI] [PubMed] [Google Scholar]
  29. Rebbeck T. R., Kantoff P. W., Krithivas K., Neuhausen S., Blackwood M. A., Godwin A. K., Daly M. B., Narod S. A., Garber J. E., Lynch H. T. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999 May;64(5):1371–1377. doi: 10.1086/302366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rebbeck T. R., Walker A. H., Zeigler-Johnson C., Weisburg S., Martin A. M., Nathanson K. L., Wein A. J., Malkowicz S. B. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000 Sep 12;67(4):1014–1019. doi: 10.1086/303096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Roberts S. A., Spreadborough A. R., Bulman B., Barber J. B., Evans D. G., Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? Am J Hum Genet. 1999 Sep;65(3):784–794. doi: 10.1086/302544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Robson M., Gilewski T., Haas B., Levin D., Borgen P., Rajan P., Hirschaut Y., Pressman P., Rosen P. P., Lesser M. L. BRCA-associated breast cancer in young women. J Clin Oncol. 1998 May;16(5):1642–1649. doi: 10.1200/JCO.1998.16.5.1642. [DOI] [PubMed] [Google Scholar]
  33. Schrag D., Kuntz K. M., Garber J. E., Weeks J. C. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000 Feb 2;283(5):617–624. doi: 10.1001/jama.283.5.617. [DOI] [PubMed] [Google Scholar]
  34. Southey M. C., Tesoriero A. A., Andersen C. R., Jennings K. M., Brown S. M., Dite G. S., Jenkins M. A., Osborne R. H., Maskiell J. A., Porter L. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer. 1999 Jan;79(1):34–39. doi: 10.1038/sj.bjc.6690008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Varley J. M., McGown G., Thorncroft M., James L. A., Margison G. P., Forster G., Evans D. G., Harris M., Kelsey A. M., Birch J. M. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999 Oct;65(4):995–1006. doi: 10.1086/302575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Verhoog L. C., Brekelmans C. T., Seynaeve C., Dahmen G., van Geel A. N., Bartels C. C., Tilanus-Linthorst M. M., Wagner A., Devilee P., Halley D. J. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999 Nov;17(11):3396–3402. doi: 10.1200/JCO.1999.17.11.3396. [DOI] [PubMed] [Google Scholar]
  37. Verhoog L. C., Brekelmans C. T., Seynaeve C., Meijers-Heijboer E. J., Klijn J. G. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000 Aug;83(3):384–386. doi: 10.1054/bjoc.2000.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Verhoog L. C., Brekelmans C. T., Seynaeve C., van den Bosch L. M., Dahmen G., van Geel A. N., Tilanus-Linthorst M. M., Bartels C. C., Wagner A., van den Ouweland A. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998 Jan 31;351(9099):316–321. doi: 10.1016/s0140-6736(97)07065-7. [DOI] [PubMed] [Google Scholar]
  39. Wagner T. M., Hirtenlehner K., Shen P., Moeslinger R., Muhr D., Fleischmann E., Concin H., Doeller W., Haid A., Lang A. H. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999 Mar;8(3):413–423. doi: 10.1093/hmg/8.3.413. [DOI] [PubMed] [Google Scholar]
  40. Welcsh P. L., Owens K. N., King M. C. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000 Feb;16(2):69–74. doi: 10.1016/s0168-9525(99)01930-7. [DOI] [PubMed] [Google Scholar]
  41. Zheng L., Pan H., Li S., Flesken-Nikitin A., Chen P. L., Boyer T. G., Lee W. H. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000 Oct;6(4):757–768. doi: 10.1016/s1097-2765(00)00075-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES